| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 26 oct 2026Próximo | Q3 2026 | Antes de apertura | 3,31 | 4,40 B |
31 ago 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.
28 ago 2026
Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...
27 ago 2026
RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
26 ago 2026
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
21 ago 2026
Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.
20 ago 2026
RESEARCH TRIANGLE PARK, N.C., August 20, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.
17 ago 2026
RESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.
12 ago 2026
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
9 ago 2026
In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...
6 ago 2026
By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme
5 ago 2026
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Generative AI In Clinical Trials Market size & share revenue was valued at approximately USD 0.74 Billion in 2025 and is expected to reach USD 0.81 Billion in 2026 and is expected to reach around USD 1.86 Billion by 2035, at a CAGR of 9.63% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are IQVIA Holdings I
